Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tight junction protein complex is a multi-protein structure located at the apical-most part of the lateral cell membrane in epithelial and endothelial cells. It serves as a primary regulator of the paracellular barrier, controlling the flow of ions and solutes while preventing the translocation of pathogens and toxins (StatPearls, NBK532240). The complex is composed of transmembrane proteins such as claudins, occludin, and junctional adhesion molecules (JAMs), which interact with intracellular scaffolding proteins like zonula occludens (ZO-1) to link the junction to the actin cytoskeleton (UniProt, Q16625). Dysfunction of these proteins is linked to various pathologies, including inflammatory bowel disease and celiac disease, where leaky barriers allow for chronic immune activation (Nature Reviews, 10.1038/nrgastro.2014.182). In oncology, specific proteins like Claudin-18.2 are targeted by monoclonal antibodies such as zolbetuximab to treat gastric cancers. Therapeutic interventions aim to either reinforce the barrier to treat inflammatory conditions or selectively open it to facilitate drug delivery across the blood-brain barrier or intestinal epithelium. Additionally, the complex plays a vital role in maintaining cell polarity, which is often lost during epithelial-mesenchymal transition in metastatic cancer.
Antagonism of zonulin-mediated tight junction disassembly; Monoclonal antibody-mediated targeting of specific claudin isoforms; Activation of chloride channels to promote junctional assembly; GLP-2 receptor agonism to promote mucosal growth and barrier integrity.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tight junction protein complex (TJ) (TJ).